ArticleBMC medicine2026
miR-155-5p drives coordinated tumor and macrophage reprogramming across multiple cancer entities.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundT cell-based immunotherapies have improved cancer treatment, however their efficacy is frequently limited by tumor-intrinsic resistance mechanisms and by the immune suppressive tumor microenvironment, counteracting tumor specific immune responses through impaired antigen presentation and the accumulation of M2-like tumor-associated macrophages. MicroRNAs have emerged as regulators of tumor cell - immune cell interactions, yet the miRNAs' capacity to coordinate anti-tumor effects across different cell types is poorly understood. This study aimed to investigate whether miR-155-5p and miR-3535 represent regulators capable of driving coordinated functional reprogramming of both, tumor cells and macrophages.
methodsHuman tumor cell lines of various cancer entities were transfected with miR-155-5p or miR-3535 and the resulting effects on immune checkpoint molecule expression and tumor cell proliferation were assessed on transcriptional and functional level. Similarly, human PBMC-derived M2 polarized macrophages were transfected with the same microRNAs, followed by analysis of the cytokine secretion patterns and by transcriptomic profiling to evaluate the macrophage polarization states and the immune-regulatory pathways involved. Transcription factor activity and pathway enrichment analyses were performed to identify the regulatory mechanisms affected.
resultsBoth miR-155-5p and miR-3535 reduced expression of the immune checkpoint molecule CD73 (NT5E) in tumor cells, while miR-155-5p additionally suppressed PD-L1 (CD274) expression. At the same time, both microRNAs reprogrammed M2-like macrophages toward a pro-inflammatory M1-like phenotype, characterized by increased TNFα and CXCL10 secretion and the induction of M1-associated gene expression. Transcriptomic analysis revealed activation of STAT1/IRF-driven inflammatory pathways and a reduced activity of ZNF703, representing a transcriptional hub associated with M2 macrophage infiltration and poor prognosis. Both microRNAs increased TAP1 expression, suggesting enhanced antigen-processing capacity. Furthermore, miR-155-5p and miR-3535 exerted anti-proliferative effects across cell lines of various tumor entities.
conclusionsmiR-155-5p and miR-3535 modulate tumor-intrinsic immune checkpoint expression and functional macrophage polarization in a coordinated way, linking tumor cell plasticity to neutralization of the immunosuppressive tumor environment. These findings highlight the potential of coordinated microRNA-mediated regulation via different cell types to overcome immune resistance mechanisms in tumors and support further investigation of microRNA-based strategies in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.